Table of Contents Table of Contents
Previous Page  6 / 40 Next Page
Information
Show Menu
Previous Page 6 / 40 Next Page
Page Background

Worth S$6 million for

three years (2010-2013),

the grant provided us a

springboard to establish

key infrastructure for

both clinical and basic

research.

In this way, NUHCS and

CVRI have become a

premier cardiovascular

research entity within

Asia-Pacific.

The Centre Grant, along with NUHCS’s

start-up support, helped build CVRI’s

foundation.

The grant helped equip and staff the

immunoassay laboratory and enabled

us to set up our Singapore-wide clinical

cohorts in heart failure, heart valve

disease and coronary heart disease.

This clinical network of research

coordinators and cardiologists has

enabled recruitment of a total of

more than 10,000 patients with heart

failure, coronary disease and heart

valve disease both within and

beyond Singapore’s borders. We

have also recruited healthy partici-

pants from the Singapore Longitudi-

nal Ageing Studies to provide a

control group.

The rst grant also enabled us to devel-

op our capacity and generate initial

ndings to apply for other grants.

Subsequently, we successfully won our

second (2013-2017) and third Centre

Grants (2017-2021) each worth S$10

million over four years.

Other grants include multiple Clinician

Scientist Awards to our key clinical

scientists (A/Prof. Lam, A/Prof. Chan,

A/Prof. Foo, Asst. Prof. Drum and A/Prof.

Lee); a Singapore Translational Re-

search Investigator Award (STaR) award

to myself; multiple individual research

grants (IRGs); the Translational and Clini-

cal Research (TCR) Flagship Pro-

gramme; and partnership contracts with

the industry, all totaling over S$50 million

over the last seven years.

In collaboration with NHCS and NUHCS,

we have now acquired one of NMRC’s

newly created collaborative Centre

Grants.

Worth S$7 million over four years, the

grant speci cally supports clinical

research projects conducted in

partnership between NUHCS and

NHCS, emphasising a new era of

productive cooperation between the

country’s two Heart Centres.

What are some of the other

achievements of CVRI?

We have also developed a national

community of cardiovascular re-

searchers with excellent integration

between the two Heart Centres and a

collaboration with Nanyang Techno-

logical University (NTU) and Prof. John

Chambers, Professor of Cardiovascu-

lar Epidemiology, Imperial College

London.

Other milestones include sophisticat-

ed screening techniques to discover

and measure multiple circulating

markers (e.g. proteins and peptides);

cardiac epigenetics

1

development by

A/Prof. Foo and Genome Institute

of Singapore; and a spread of world-

class publications including A/Prof.

Lee’s sleep apnoea research (fea-

tured in

Pulse Issue 27, page 31)

. I

feel heartened when our team makes

a major step forward.

Today, we have a laboratory that

can measure heart-related biomark-

ers

2

and set up our own measurement

methods. We now have a growing

team of clinician scientists with

remarkable abilities and talent. They

include approximately ve senior

staff and 70-80 assistant staff in the

wet lab facilities based on the 8

th

oor of the Centre for Translational

Medicine building (MD6), a clinical

network throughout Singapore’s

major hospitals and a regional collab-

orative network of more than a dozen

Asia-Paci c nations involving another

200 staff.

I am grati ed and proud to make new

discoveries that can make a differ-

ence to Singapore and the world. For

instance, we have prospectively de-

monstrated for the rst time that

certain types of heart failure are less

common and carry better outcomes.

NUHCS PULSE

Issue 29

06